Services on Demand
Journal
Article
Indicators
- Cited by SciELO
- Access statistics
Related links
- Similars in SciELO
Share
Gaceta médica de México
On-line version ISSN 2696-1288Print version ISSN 0016-3813
Abstract
GARCIA-JUAREZ, Ignacio et al. Sofosbuvir plus glecaprevir/pibrentasvir as salvage therapy after liver transplantation in NS5A inhibitor-experienced patients. A case series. Gac. Méd. Méx [online]. 2023, vol.159, n.4, pp.338-344. Epub Sep 25, 2023. ISSN 2696-1288. https://doi.org/10.24875/gmm.m23000781.
Background:
Treatment of chronic hepatitis C virus (HCV) infection with direct-acting antivirals achieves a sustained virologic response rates higher than 95%. However, virologic failure remains a clinical challenge, and data on retreatment are limited, especially in special populations such as liver transplant (LT) recipients.
Objective:
This study evaluated the sofosbuvir plus glecaprevir-pibrentasvir (GLE/PIB) regimen in LT recipients who had failed to a nonstructural protein 5A (NS5A) inhibitor-based regimen.
Material and methods:
Retrospective study of 111 liver transplant recipients between January 2018 and December 2020; 18 patients presented with HCV recurrent infection after LT, out of whom three had a history of at least one NS5A inhibitor-based regimen. Salvage therapy with sofosbuvir plus GLE/PIB was started for 12 weeks; baseline characteristics and outcomes were recorded.
Results:
All three patients (100%) achieved an undetectable HCV viral load 12 weeks after treatment completion. No serious adverse events were observed.
Conclusion:
In our series, sofosbuvir plus GLE/PIB for 12 weeks is an effective and safe salvage therapy after LT in patients previously treated with NS5A inhibitors.
Keywords : Direct-acting antivirals; Glecaprevir; Pibrentasvir; Rescue therapy; Liver transplantation; Hepatitis C virus.